Harpreet S Bajaj

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 36

Top Venues

Diabetes, obesity & metabolism

Diabetes care

Journal of the American Heart Association

The New England journal of medicine

Mount Sinai Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Mount Sinai Hospital Mar 04 2016

Canada

Research Associate :: Endocrinology

LMC Diabetes and Endocrinology Jul 07 2009

Canada

Epidemiologist & Endocrinologist :: Diabetes and Endocrinology

Cleveland Clinic Jul 01 2007 - Jun 30 2009

United States

Clinical Fellow :: Endocrinology

Hennepin County Medical Center Jun 23 2004 - Jun 23 2007

United States

Resident :: Internal Medicine

Publications

Harpreet S Bajaj, Björg Ásbjörnsdóttir, Tanvir Johanning Bari, Kamilla Begtrup, Tina Vilsbøll, Julio Rosenstock
Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials. Diabetes, obesity & metabolism (2024)
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis-Tsimikas, Tadej Battelino
Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Diabetes care 47 (4) (2024)
Sheldon W Tobe, Thomas A Mavrakanas, Harpreet S Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L Neuen, Vlado Perkovic, Kenneth W Mahaffey, Wally Rapattoni, Fernando G Ang
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials. Diabetes care 47 (3) (2024)
Sheldon W Tobe, Thomas A Mavrakanas, Harpreet S Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L Neuen, Vlado Perkovic, Kenneth W Mahaffey, Wally Rapattoni, Fernando G Ang
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE trials. Diabetes care (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis-Tsimikas, Tadej Battelino
Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Diabetes care 47 (4) (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Tanvir Johanning Bari, Kamilla Begtrup, Tina Vilsbøll, Julio Rosenstock
Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials. Diabetes, obesity & metabolism 26 (9) (2024)
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis-Tsimikas, Tadej Battelino
Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-Standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Diabetes care (2024)
Sheldon W Tobe, Thomas A Mavrakanas, Harpreet S Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L Neuen, Vlado Perkovic, Kenneth W Mahaffey, Wally Rapattoni, Fernando G Ang
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials. Diabetes care 47 (3) (2024)
Sheldon W Tobe, Thomas A Mavrakanas, Harpreet S Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L Neuen, Vlado Perkovic, Kenneth W Mahaffey, Wally Rapattoni, Fernando G Ang
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials. Diabetes care 47 (3) (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis-Tsimikas, Tadej Battelino
Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Diabetes care 47 (4) (2024)
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis-Tsimikas, Tadej Battelino
Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Diabetes care 47 (4) (2024)
Ronnie Aronson, Ruth E Brown, Lisa Chu, Harpreet S Bajaj, Hasnain Khandwala, Alexander Abitbol, Nadia Malakieh, Ronald Goldenberg
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes, obesity & metabolism 25 (4) (2023)
Ronnie Aronson, Ruth E Brown, Lisa Chu, Harpreet S Bajaj, Hasnain Khandwala, Alexander Abitbol, Nadia Malakieh, Ronald Goldenberg
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes, obesity & metabolism 25 (4) (2023)
Ronnie Aronson, Ruth E Brown, Lisa Chu, Harpreet S Bajaj, Hasnain Khandwala, Alexander Abitbol, Nadia Malakieh, Ronald Goldenberg
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes, obesity & metabolism 25 (4) (2023)
Harpreet S Bajaj, Jens Aberle, Melanie Jane Davies, Anders Meller Donatsky, Marie Frederiksen, Dilek Gogas Yavuz, Amoolya Gowda, Ildiko Lingvay, Bruce W Bode
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial. Annals of internal medicine (2023)
Hiren Patel, Kamlesh Khunti F MedSci, Helena W Rodbard, Harpreet S Bajaj, Ross Bray, Zbigniew Kindracki, Angel Rodríguez
Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes, obesity & metabolism (2023)
Irene Hramiak, Ulagamadesan Venkatesan, Lawrence Alan Leiter, Jean-François Yale, Harpreet S Bajaj, John Stewart, Marie-Josée Toutounji, Stewart B Harris
Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial. Diabetes, obesity & metabolism 24 (10) (2022)
Ronnie Aronson, Ruth E Brown, Lisa Chu, Harpreet S Bajaj, Hasnain Khandwala, Alexander Abitbol, Nadia Malakieh, Ronald Goldenberg
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycemic ThErapy (IMMEDIATE): A Randomized Clinical Trial. Diabetes, obesity & metabolism (2022)
Ronnie Aronson, Ruth E Brown, Lisa Chu, Harpreet S Bajaj, Hasnain Khandwala, Alexander Abitbol, Nadia Malakieh, Ronald Goldenberg
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes, obesity & metabolism (2022)
Athena Philis-Tsimikas, Harpreet S Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David L Russell-Jones, Julio Rosenstock
Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes, obesity & metabolism (2022)
Harpreet S Bajaj, Richard M Bergenstal, Andreas Christoffersen, Melanie J Davies, Amoolya Gowda, Joakim Isendahl, Ildiko Lingvay, Peter A Senior, Robert J Silver, Roberto Trevisan, Julio Rosenstock
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Diabetes care 44 (7) (2021)
Stephen C Bain, Ellen Burgess, Priya Vart, Glenn M Chertow, Fan Fan Hou, Niels Jongs, John Joseph Valentine McMurray, Ricardo Correa-Rotter, Harpreet S Bajaj, Bergur V Stefansson, Robert D Toto, Anna Maria Langkilde, David C Wheeler, Hiddo J Lambers Heerspink, null null
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes care 44 (8) (2021)
Thomas R Pieber, Harpreet S Bajaj, Simon R Heller, Ting Jia, Kamlesh Khunti F MedSci, David C Klonoff, Steen Ladelund, Lawrence Alan Leiter, Lily Wagner, Athena Philis-Tsimikas
Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial. Diabetes, obesity & metabolism (2021)
Harpreet S Bajaj, Melonie Burrows, Jessica Blavignac, Emilia Paron, Fernando Camacho, Errol Gould, Maxime Barakat
Extended-release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials. Diabetes, obesity & metabolism 23 (3) (2021)
Harpreet S Bajaj, Ruth E Brown, Dishay Jiandani, Karri Venn, Hani Al-Asaad, Hasnain Khandwala, Oren Steen, Suzan Abdel-Salam, Ronnie Aronson
Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT. Diabetes, obesity & metabolism 22 (10) (2020)
Harpreet S Bajaj, Itamar Raz, Ofri Mosenzon, Sabina A Murphy, Aliza Rozenberg, Ilan Yanuv, Deepak L Bhatt, Lawrence Alan Leiter, Darren K McGuire, John P H Wilding, Ingrid A M Gause-Nilsson, Marc S Sabatine, Stephen D Wiviott, Avivit Cahn
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. Diabetes, obesity & metabolism 22 (7) (2020)
Julio Rosenstock, Harpreet S Bajaj, Andrej Janez, Robert Silver, Kamilla Begtrup, Melissa Voigt Hansen, Ting Jia, Ronald M Goldenberg, null null
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. The New England journal of medicine 383 (22) (2020)
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, Megumi Oshima, Rajiv Agarwal, George L Bakris, Harpreet S Bajaj, Scott Bull, Christopher P Cannon, David M Charytan, Dick de Zeeuw, Gian Luca Di Tanna, Tom Greene, Hiddo J L Heerspink, Adeera Levin, Bruce Neal, Carol Pollock, Rose Qiu, Tao Sun, David C Wheeler, Hong Zhang, Bernard Zinman, Norman Rosenthal, Vlado Perkovic, null null
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology : JASN 31 (5) (2020)
Harpreet S Bajaj, Bernard Zinman
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. Physiology (Bethesda, Md.) 33 (3) (2019)
Vincent Woo, Alan Bell, Maureen Clement, Luis Noronha, Michael A Tsoukas, Fernando Camacho, Shana Traina, Natasha Georgijev, Matthew D Culham, Jennifer B Rose, Wally Rapattoni, Harpreet S Bajaj
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice. Diabetes, obesity & metabolism 21 (3) (2018)
Harpreet S Bajaj, Chenglin Ye, Esha Jain, Karri Venn, Eden Stein, Ronnie Aronson
Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study). Diabetes, obesity & metabolism 20 (1) (2017)

Harpreet S Bajaj.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Harpreet S Bajaj